Nicoasia International
Premium veterinary pharmaceutical manufacturer producing state-of-the-art medicines, anti-infectives, and therapeutic treatments. Headquartered in Cyprus and distributed with strict quality compliance across UAE & Oman.
Company Overview
Nicoasia International is a premier pharmaceutical enterprise based in Cyprus, dedicated to formulating and manufacturing high-grade veterinary medicines, chemotherapeutic agents, and targeted anti-infectives. Operating under stringent European Union Good Manufacturing Practices (EU-GMP), Nicoasia leverages pharmaceutical innovation to combat systemic infectious diseases in commercial livestock, poultry, and equine species.
With robust molecular testing and stable delivery mechanisms, Nicoasia's injectable and oral therapeutics are designed for maximum bioavailability, ensuring rapid recovery and minimal withdrawal periods for food-producing animals.
Product Range & Therapeutic Verticals
Nicoasia's product range specializes in veterinary pharmaceutical efficacy:
Why MAAT Partners with Nicoasia
Our partnership with Nicoasia is centered around therapeutic reliability and strict product safety. MAAT partners with them because of:
EU-GMP Standard
Manufactured under European regulations, offering premium safety assurances.
High Bioavailability
Injectables formulated for fast clinical onset and rapid disease containment.
Comprehensive Regulatory Support
Streamlined data packages for MOCCAE medicine registrations.
Trusted Delivery
Long-standing supply reliability serving key clinics across UAE & Oman.
Featured Nicoasia Products
Explore premium veterinary pharmaceuticals manufactured by Nicoasia and distributed by MAAT Group.
Tylosin Plus
Antibiotic formulation targeting respiratory and mycoplasma-associated infections.
Almox LA
Long-acting amoxicillin antibiotic injection for systemic bacterial infections.
Maxin
Broad-spectrum antimicrobial preparation for mixed bacterial infections.